• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Divis Labs gets US FDA import alert

financialexpressMarch 22, 2017

Tag: Import Alert , FDA

US FDA has issued an Import Alert 66-40 to Divis Laboratories for its Unit-II at Visakhapatnam, Andhra Pradesh. However, the US agency has exempted 10 products manufactured in the plant from the alert list.

The exempted products are Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate and 2,4-wing active ester.

The company has announced that it is working with third party consultants to address the concerns of the USFDA and meet the compliance requirements.

Previous:Bausch + Lomb and Nicox Announce PDUFA Date for Novel Glaucoma Candidate Latanoprostene Bunod

Next:Merck Accelerator hits new peak of applications

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Divis Labs gets US FDA import alert | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Etoposide( FDA)

Etoposide( FDA)
Sirolimus (FDA)

Sirolimus (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service